A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
about
Combination therapy in combating cancer.Proteomic analyses of brain tumor cell lines amidst the unfolded protein responseInhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
P2860
A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@en
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@nl
type
label
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@en
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@nl
prefLabel
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@en
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@nl
P2093
P2860
P1476
A phase II trial of tamoxifen ...... h recurrent malignant gliomas.
@en
P2093
Dawit Aregawi
Ellen K Innis
Howard A Fine
Teri N Kreisl
Yazmín Odia
P2860
P2888
P304
P356
10.1007/S11060-015-1894-Y
P577
2015-08-19T00:00:00Z